Selectis Health Audit Committee Member Resigns, Raising Governance Concerns
Summary
David Furstenberg has resigned from Selectis Health's Board of Directors and Audit Committee, effective March 30, 2026, with no reason for his departure disclosed. This resignation, particularly from a key oversight committee, raises questions about corporate governance and potential internal issues at the company. It follows closely on the heels of the board's 'no recommendation' regarding Black Pearl Equities' $5.05 per share cash offer, adding to the narrative of potential internal dynamics and strategic uncertainty. Traders will likely view this as a negative signal and monitor for further board changes or explanations.
At the time of this announcement, GBCS was trading at $4.20 on OTC in the Life Sciences sector, with a market capitalization of approximately $12.9M. The 52-week trading range was $0.41 to $6.25. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.